What is Abbott Laboratories (ABT)?

Abbott Laboratories (ABT) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of ABT?

The current price of ABT is $103.29. Prices are updated in real time on Stocks360.

What is ABT's price-to-earnings (PE) ratio?

ABT's trailing twelve-month PE ratio is 38.26, based on current price and earnings per share data available on Stocks360.

What is ABT's market capitalization?

ABT's market capitalization is $178,731,292,228.00, placing it in the large-cap tier.

Does ABT pay a dividend?

Yes. ABT has a trailing twelve-month dividend yield of 0.02%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Abbott Laboratories (ABT)

Stock analysis · NYSE · Healthcare · Medical - Devices

$103.29

Market Cap

$178.73B

PE (TTM)

38.26

EPS (TTM)

N/A

Dividend Yield

2.44%

Beta

0.58

Day Range

$101.91 – $104.28

52-wk Range

$81.97 – $132.03

Avg Volume

N/A

Volume

3.88M

Abbott Laboratories (ABT) is a publicly traded company in the Healthcare sector. Latest price: $103.29. Market cap $178.73B. Trailing PE 38.26. Dividend yield 2.44%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-27 · $127.18 2026-10-27 · $103.25 (-18.82%)

Earnings

Most Recent

Oct 21, 2026

EPS $1.42 vs est. $1.42

Beat by $0.00

Next Earnings

Jan 28, 2027

EPS estimate $1.64

Proprietary Signals

Signal snapshot temporarily unavailable.

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, p…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	38.26×
P/S (TTM)	3.71×
P/B	3.51×
P/FCF (TTM)	20.50×
EV / EBITDA	21.24×
EV / Sales	4.28×
Earnings Yield	2.62%
Free Cash Flow Yield	4.88%
Dividend Yield	2.44%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$206.24B
Revenue (TTM)	$48.23B
Net Income (TTM)	$4.68B
Free Cash Flow (TTM)	$8.46B
Net Debt	$27.50B
Working Capital	$6.70B
Gross Margin	57.12%
Operating Margin	15.24%
Net Margin	9.75%
Return on Equity	9.12%
Return on Invested Capital	5.58%